Evidence map›Paper›PMID 23591953›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2013

Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.

Cristina Nanni, Riccardo Schiavina, Stefano Boschi, Valentina Ambrosini, Cinzia Pettinato, Eugenio Brunocilla, Giuseppe Martorana, Stefano Fanti

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. [Tomography (Ann Arbor, Mich.) · 2022
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Understanding and ImprovingProstate cancer · 2020
    Review
  12. Saving costs in cancer patient management through molecular imaging.European journal of nuclear medicine and molecular imaging · 2017
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. PET Tracers Beyond FDG in Prostate Cancer.Seminars in nuclear medicine · 2016
    Review
  19. Article
  20. PET/CT is a cost-effective tool against cancer: synergy supersedes singularity.European journal of nuclear medicine and molecular imaging · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cristina NanniOU Nuclear Medicine, Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi, Via Massarenti 9, 40138 Bologna, Italy. cnanni@aosp.bo.it
Riccardo Schiavina
Stefano Boschi
Valentina Ambrosini
Cinzia Pettinato
Eugenio Brunocilla
Giuseppe Martorana
Stefano Fanti

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe assessed the rate of detection rate of recurrent prostate cancer by PET/CT using anti-3-(18)F-FACBC, a new synthetic amino acid, in comparison to that using (11)C-choline as part of an ongoing prospective single-centre study.

methodsIncluded in the study were 15 patients with biochemical relapse after initial radical treatment of prostate cancer. All the patients underwent anti-3-(18)F-FACBC PET/CT and (11)C-choline PET/CT within a 7-day period. The detection rates using the two compounds were determined and the target-to-background ratios (TBR) of each lesion are reported.

resultsNo adverse reactions to anti-3-(18)F-FACBC PET/CT were noted. On a patient basis, (11)C-choline PET/CT was positive in 3 patients and negative in 12 (detection rate 20%), and anti-3-(18)F-FACBC PET/CT was positive in 6 patients and negative in 9 (detection rate 40%). On a lesion basis, (11)C-choline detected 6 lesions (4 bone, 1 lymph node, 1 local relapse), and anti-3-(18)F-FACBC detected 11 lesions (5 bone, 5 lymph node, 1 local relapse). All (11)C-choline-positive lesions were also identified by anti-3-(18)F-FACBC PET/CT. The TBR of anti-3-(18)F-FACBC was greater than that of (11)C-choline in 8/11 lesions, as were image quality and contrast.

conclusionOur preliminary results indicate that anti-3-(18)F-FACBC may be superior to (11)C-choline for the identification of disease recurrence in the setting of biochemical failure. Further studies are required to assess efficacy of anti-3-(18)F-FACBC in a larger series of prostate cancer patients.

Indexed as

Carbon RadioisotopesCarboxylic AcidsCholineCyclobutanesPositron-Emission TomographyRadiopharmaceuticalsAgedHumansLimit of DetectionMaleMiddle AgedMultimodal ImagingNeoplasm MetastasisNeoplasm Recurrence, LocalProstate-Specific AntigenProstatic NeoplasmsCarbon RadioisotopesCarboxylic AcidsCholineCyclobutanesfluciclovine F-18Prostate-Specific AntigenRadiopharmaceuticals

Identifiers

PMID23591953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.